Visual Acuity and Contrast Sensitivity

Published on 08/03/2015 by admin

Filed under Opthalmology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1843 times

Chapter 11 Visual Acuity and Contrast Sensitivity

Visual acuity tests

Chart design

Optotypes

Most familiar acuity tests require the subject to identify letters arrayed in rows of decreasing size. The so-called Snellen acuity test is the prime example, although Snellen acuity now usually refers to a way of reporting test results rather than to any particular type of chart. To facilitate testing of young children and people unfamiliar with the Latin alphabet, other optotype tests based on the tumbling E, Landolt C, numerals, or simple pictures of familiar objects are also used. Visual acuity can also be assessed with grating patterns, but grating acuity often overestimates Snellen acuity in patients with age-related maculopathy,3 typically by a factor of 2 or more.

The NAS-NRC recommends that the Landolt C test be used as the standard by which other acuity tests are compared. The Landolt C is a broken circle in which the width of the break and the stroke width are both equal to one-fifth the height of the C. The ring is shown with the break at one of four locations, and the subject responds by saying “right,” “down,” “up,” or “left,” or by pointing in the appropriate direction.

There are several advantages to the Landolt C test, including equal difficulty of all targets (unlike letters that vary in degree of difficulty), sensitivity to astigmatic refractive error, and suitability for use with illiterate subjects. However, the Landolt C test is not widely used because it has a guessing rate of 25%, so an alternative is to standardize another optotype set by comparing acuities obtained with it to Landolt C test acuities. The Sloan letters,4 a set of 10 upper-case sans serif letters, are the most popular substitute. An acuity chart based on Sloan letters was developed for the Early Treatment Diabetic Retinopathy Study (ETDRS)5 and is illustrated in Fig. 11.1. The original ETDRS chart has been replaced by the 2000 series revised ETDRS chart that more accurately equates the difficulty of letters on all lines. The ETDRS charts are the most widely used acuity charts for clinical research.

image

Fig. 11.1 The Early Treatment Diabetic Retinopathy Study (ETDRS) acuity chart.

(Reproduced with permission from Ferris FL III, Kassof PA, Bresnick GH, et al. New visual acuity charts for clinical research. Am J Ophthalmol 1982;94:91–96.)

Testing procedure

Luminance and contrast

Whatever the test distance, the chart must be adequately illuminated and of high contrast. Illumination standards vary from 100 cd/m2 in the USA to 300 cd/m2 in Germany. Increasing chart luminance improves visual acuity in normal subjects, but reaches a plateau at about 200 cd/m2.12 Various types of visual dysfunction can change the effects of luminance on acuity. For example, patients with retinitis pigmentosa may show a decrease in acuity at higher luminance, whereas patients with age-related macular degeneration often continue to improve at luminances well above the normal plateau.13 A luminance standard of 100 cd/m2 can be justified because it represents good room illumination for ordinary reading material. Furthermore, most of the currently proposed standards would yield the same acuity scores, plus or minus one letter (assuming five letters per line and a 0.1 log unit size progression) in normal subjects.

The relationship of visual acuity to letter contrast follows a square-root law.14 For example, decreasing contrast by a factor of 2 would decrease acuity by roughly a factor of 1.4. The NAS-NRC recommends that letter contrast be at least 0.85. Transilluminated, projection, and reflective charts (wall charts) can all meet these standards, but some transilluminated charts are deficient in luminance, and some projection systems lack sufficient luminance and contrast. Accurate calibration requires a spot photometer, for which procedures are described in the NAS-NRC document.1

Scoring

Until recently, visual acuity tests were usually scored line by line with the patient being given credit for a line when a criterion number of letters were identified correctly. The NAS-NRC recommends that at least two-thirds of the letters on a line be correctly identified to qualify for passing. Allowing a small proportion of errors improves test reliability.17 For tests that follow the recommended format of an equal number of letters on each line and a constant progression of letter sizes, it is preferable to give partial credit for each letter correctly identified. This is commonly done by counting the number of letters read correctly on the entire chart and converting this to an acuity score by means of a simple formula that values each letter as L/N, where L = difference in acuity between adjacent lines and N = number of letters per line. So for a chart with five letters per line and a 0.1 logMAR (see below) progression from line to line (such as the standard ETDRS chart) each correct letter is worth 0.1/5 = 0.02 logMAR. Although differences between scoring methods are usually small, it has been shown2,6,18 that letter-by-letter scoring is more reproducible than line-by-line scoring.

The most familiar method for reporting visual acuities is the Snellen fraction. The numerator of the Snellen fraction indicates the test distance, and the denominator indicates the relative size of the letter, usually in terms of the distance at which the stroke width would subtend a visual angle of 1 minute. Thus “20/40” indicates that the actual test distance was 20 feet and that the strokes of the letters would subtend 1 minute of arc at 40 feet.

To simplify comparison of acuities measured at different distances, the minimum angle of resolution (MAR) should be used. The MAR is the visual angle corresponding to stroke width in minutes of arc and is equal to the reciprocal of the Snellen fraction. Visual acuities are frequently converted to log10 and reported as “logMAR.” For example, 20/20 acuity corresponds to a MAR of 1 minute of arc, or a logMAR of 0, and 20/100 acuity corresponds to a MAR of 5 minutes of arc, or a logMAR of 0.7 (as does an acuity of 2/10 or 6/30). The MAR and logMAR scales increase with worsening acuity. One often sees visual acuities reported as the decimal equivalent of the Snellen fraction. However acuities are more normally distributed when converted to logMAR rather than decimal values. Moreover, decimals give the false impression that acuity scores can be equated with overall loss of visual function. For example, an acuity of 0.1 (the decimal equivalent of 20/200) may misleadingly suggest that the patient has retained 10% of residual visual function.

Near and reading acuity tests

Near acuity is usually tested to evaluate reading vision. These tests are particularly important for prescribing visual aids for persons with low vision. Near acuity has been shown to be a better predictor of the optimal magnification needed by visually impaired readers than traditional distance acuity.19

Although some near acuity tests are simply reduced versions of distance acuity charts, most tests consist of printed text, either unrelated words or complete sentences or paragraphs, covering a range of sizes. Near acuity tests are even less standardized than distance acuity tests.

Specifying letter size

As with all acuity tests, the most critical parameter is the visual angle subtended by the optotype. Many systems have been devised for specification of print size. One of the most common is the Jaeger J notation. Jaeger notation is based on a numeric scale (J1, J2, and so on) that follows no logical progression except that larger numbers correspond to larger print sizes. Furthermore, print with the same J specification can vary by as much as 90% from one test manufacturer to another.20

Alternatives to the Jaeger notation are the typesetter’s point system, the British N system, and the M notation introduced by Sloan. The typesetter’s point is commonly used to specify letter size for printed text and is equal to 0.32 mm (1/72 inch). However, the measurement refers to the size of the metal slug that contains the letter and varies from one font to another. A study21 of the effect of font on reading speed showed that the nominal sizes of printed text can be very misleading. Of four fonts, all labeled as 12 point, one was much more legible than the other three. But it turned out that the more legible font was actually larger than the others and when equated for real size there was no difference in legibility.

The British N system standardized the point size specification by adopting the Times Roman font. Sloan’s M notation,4 widely used in the USA, is standardized according to the height of a lower-case “x.” A lower-case 1M letter subtends 5 minarc at a 1-meter viewing distance and corresponds roughly to the size of ordinary newsprint. None of the print size specifications can be used for quantitative comparisons unless viewing distance is also specified. For example, 1M print read at a distance of 40 cm would be recorded as 0.40/1.00M.

Words versus continuous text

One issue that remains unresolved is whether near acuity tests should be based on unrelated words or meaningful text. An argument in favor of unrelated words is that contextual information promotes guessing and may lead to an overestimate of near acuity.22 In addition, the presence of semantic context introduces variability because of cognitive intellectual factors that may mask the visual factors of primary concern.23 On the other side it is argued that the main reason for measuring near acuity is to gain information about reading performance. Since context is normally available to the reader, a reading test that includes meaningful text will be a better indicator of everyday performance. Fortunately, reading speed for meaningful text is highly correlated with reading speed for unrelated words.24

The MNREAD test25 uses meaningful text to evaluate near acuity. The test is composed of 19 standardized sentences in a logarithmic progression of sizes. Each sentence is 55 characters and the words are drawn from a controlled vocabulary. The test can be used to measure reading acuity (the smallest print size that can be read), maximum reading speed, and critical print size (the smallest print size for maximum reading speed). The test–retest variability for the MNREAD test has been assessed in patients with macular disease26 and the coefficient of repeatability was found to be greater than 65 words/minute. The high level of variability may be due, in part, to the short sentences. The International Reading Speed Test (IReST)27 uses 150-word paragraphs of continuous text to measure reading speed, which should yield more reproducible measures. The IReST is available in 17 languages.

Electronic acuity tests

Video-based acuity tests have been available since the 1980s, but did not become popular until the introduction of inexpensive LCD monitors in recent years. These electronic tests include computer software that can be used with the experimenter’s own computer hardware (such as the Freiburg Acuity and Contrast Test (FrACT)), devices that display optotypes under operator control (such as the Test Chart 2000) and systems that administer, score, and store the results of the acuity measurement (such as the E-ETDRS and COMPlog systems).

Electronic tests offer several potential advantages over paper-based tests:

Contrast sensitivity tests

Utility of contrast sensitivity tests

For people with normal vision, contrast sensitivity and visual acuity are correlated. However, various types of visual dysfunction, including cerebral lesions,30 optic neuritis related to multiple sclerosis,31 glaucoma,32 diabetic retinopathy,33 and cataract,34 may cause a reduction in contrast sensitivity despite near-normal visual acuity. This led to the suggestion that contrast sensitivity might serve as a tool for differential diagnosis and screening. However, there is no pattern of CSF loss that is unique to any particular vision disorder. The types of CSF measured in patients with macular disease or glaucoma can be similar to the CSFs measured in cataract patients, although detailed analyses with targets of different size or at different retinal eccentricities may help distinguish between various causes of the loss. It is argued that contrast sensitivity tests are more sensitive to early eye disease than visual acuity. While this may be true, much of the apparent difference in sensitivity is due to careless measurement of visual acuity (poorly designed charts and test procedures). Even if the test were more sensitive, its lack of specificity for distinguishing between ocular and retinal/neural disorders limits its usefulness as a screening test.35

The real value of clinical contrast sensitivity testing is to gain a better understanding of the impact of visual impairment on functional ability. Several studies have demonstrated that contrast sensitivity is useful for understanding the difficulties in performing everyday visual tasks faced by older people with essentially normal vision36 and by patients with retinal disease.37,38 Studies have shown that contrast sensitivity loss leads to mobility problems and difficulty recognizing signs or faces,39 even when adjusted for loss of acuity.40

The association of contrast sensitivity with functional ability argues in favor of including contrast sensitivity measurements in clinical trials. Although visual acuity is the most common primary visual outcome measure, several studies have included contrast sensitivity as a secondary outcome. Considering both visual acuity and contrast sensitivity when assessing the outcomes of clinical trials may provide a more complete picture of the effects of treatment on vision than either measure alone. Examples where contrast sensitivity has been used as a secondary outcome include the Optic Neuritis Treatment Trial,41 the TAP study of photodynamic therapy for age-related macular degeneration (AMD),42 and the ABC trial of bevacizumab for AMD.43

Methods

Common contrast sensitivity tests

Traditional methods for measuring contrast sensitivity require relatively expensive and sophisticated equipment – typically a computer-controlled video monitor – and employ time-consuming psychophysical procedures. However, several simpler contrast sensitivity tests have been developed primarily for clinical use. These include the Functional Acuity Contrast Test44 (FACT, replacement for the popular Vistech VCTS chart) and the CSV-1000,45 sine-wave grating tests in chart form, and various low-contrast optotype tests such as the Lea test,46 the Pelli–Robson letter chart,17 the Melbourne Edge Test47 and the Mars Letter Contrast Sensitivity Test.48 Examples of three of the most commonly used clinical contrast sensitivity tests are illustrated in Fig. 11.2.

image image image

Fig. 11.2 Commonly used clinical contrast sensitivity tests. (A) Vistech VCTS 6500.

(Courtesy of Vistech Consultants, Dayton, OH.) (B) Lea numbers low-contrast acuity test. (Courtesy of Good-Lite, Streamwood, IL.) (C) Pelli–Robson letter sensitivity chart. (Reproduced with permission from Pelli DG, Robson JG, Wilkins AJ. The design of a new letter chart for measuring contrast sensitivity. Clin Vis Sci 1988;2:187–200.)

References

1 NAS-NRC. Recommended standard procedures for the clinical measurement and specification of visual acuity. Report of working group 39. Adv Ophthalmol. 1980;41:103–148.

2 British Standards Institution. Specification for test charts determining distance visual acuity. London: British Standards House.

3 White JM, Loshin DS. Grating acuity overestimates Snellen acuity in patients with age-related maculopathy. Optom Vis Sci. 1989;66:751–755.

4 Sloan LL, Rowland WM, Altman A. Comparison of three types of test target for the measurement of visual acuity. Q Rev Opthalmol. 1952;8:4–16.

5 Ferris FL, Kassoff A, Bresnick GH, et al. New visual acuity charts for clinical research. Am J Ophthalmol. 1982;94:91–96.

6 Raasch T, Bailey I, Bullimore M. Repeatability of visual acuity measurement. Optom Vis Sci. 1998;75:342–348.

7 Flom MC, Bedell HE. Identifying amblyopia using associated conditions, acuity, and nonacuity features. Am J Optom Physiol Opt. 1985;62:153–160.

8 Kitchin JE, Bailey I. Task complexity and visual acuity in senile macular degeneration. Aust J Optom. 1981;64:235–242.

9 Strong G, Woo GC. A distance visual acuity chart incorporating some new design features. Arch Ophthalmol. 1985;102:44.

10 Schulze-Bonsel K, Feltgen N, Burau H, et al. Visual acuities “hand motion” and “counting fingers” can be quantified with the Freiburg visual acuity test. Invest Ophthalmol Vis Sci. 2006;47:1236–1240.

11 Dong LM, Hawkins BS, Marsh MJ. Consistency between visual acuity scores obtained at different test distances: theory vs observations in multiple studies. Arch Ophthalmol. 2002;120:1523–1533.

12 Sheedy JE, Bailey IL, Raasch TW. Visual acuity and chart luminance. Am J Optom Physiol Opt. 1984;61:595–600.

13 Sloan LL, Habel A, Feiock K. High illumination as an auxiliary reading aid in diseases of the macula. Am J Ophthalmol. 1973;76:745–757.

14 Legge GE, Rubin GS, Luebker A. Psychophysics of reading. V. The role of contrast in normal vision. Vision Res. 1987;27:1165–1177.

15 Higgins KE, Jaffe MJ, Coletta NJ, et al. Spatial contrast sensitivity. Importance of controlling the patient’s visibility criterion. Arch Ophthalmol. 1984;102:1035–1041.

16 Rubin GS. Reliability and sensitivity of clinical contrast sensitivity tests. Clin Vis Sci. 1988;2:169–177. 1988

17 Pelli DG, Robson JG, Wilkins AJ. The design of a new letter chart for measuring contrast sensitivity. Clin Vis Sci. 1988;2:187–199.

18 Arditi A, Cagenello R. On the statistical reliability of letter-chart visual acuity measurements. Invest Ophthalmol Vis Sci. 1993;34:120–129.

19 Lovie-Kitchin JE, Whittaker SG. Prescribing near magnification for low vision patients. Clin Exp Optom. 1999;82:214–224.

20 Jose RT, Atcherson RM. Type-size variability for near-point acuity tests. Am J Optom Physiol Opt. 1977;54:634–638.

21 Rubin GS, Feely M, Perera S, et al. The effect of font and line width on reading speed in people with mild to moderate vision loss. Ophthalm Physiol Opt. 2006;26:545–554.

22 Sloan LL, Brown DJ. Reading cards for selection of optical aids for the partially sighted. Am J Ophthalmol. 1963;55:1187–1199.

23 Baldasare J, Watson GR, Whittaker SG, et al. The development and evaluation of a reading test for low vision individuals with macular loss. J Visual Impairment Blindness. 1986;1986:785–789.

24 Legge GE, Ross JA, Luebker A, et al. Psychophysics of reading. VIII. The Minnesota Low-Vision Reading Test. Optom Vis Sci. 1989;66:843–853.

25 Mansfield JS, Legge GE, Bane MC. Psychophysics of reading. XV: Font effects in normal and low vision. Invest Ophthalmol Vis Sci. 1996;37:1492–1501.

26 Patel PJ, Chen FK, Da Cruz L, et al. Test–retest variability of reading performance metrics using MNREAD in patients with age-related macular degeneration. Invest Ophthalmol Visual Sci. 2011;52:3854–3859.

27 Hahn GA, Penka D, Gehrlich C, et al. New standardised texts for assessing reading performance in four European languages. Br J Ophthalmol. 2006;90:480–484.

28 Laidlaw DA, Tailor V, Shah N, et al. Validation of a computerised logMAR visual acuity measurement system (COMPlog): comparison with ETDRS and the electronic ETDRS testing algorithm in adults and amblyopic children. Br J Ophthalmol. 2008;92:241–244.

29 Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127:1115–1128.

30 Bodis-Wollner I. Visual acuity and contrast sensitivity in patients with cerebral lesions. Science. 1972;178:769–771.

31 Regan D, Silver R, Murray TJ. Visual acuity and contrast sensitivity in multiple sclerosis-hidden visual loss: an auxiliary diagnostic test. Brain. 1977;100:563–579.

32 Bron AJ. Contrast sensitivity changes in ocular hypertension and early glaucoma. Surv Ophthalmol. 1989;33(Suppl):405–406. discussion 9–11

33 Howes SC, Caelli T, Mitchell P. Contrast sensitivity in diabetics with retinopathy and cataract. Aust J Ophthalmol. 1982;10:173–178.

34 Rubin GS, Adamsons IA, Stark WJ. Comparison of acuity, contrast sensitivity, and disability glare before and after cataract surgery. Arch Ophthalmol. 1993;111:56–61.

35 Legge GE, Rubin GS. The contrast sensitivity function as a screening test: A critique. Am J Optom Physiol Opt. 1986;63:265–270.

36 West SK, Rubin GS, Broman AT, et al. How does visual impairment affect performance on tasks of everyday life? The SEE project. Salisbury Eye Evaluation. Arch Ophthalmol. 2002;120:774–780.

37 Lennerstrand G, Ahlström CO. Contrast sensitivity in macular degeneration and the relation to subjective visual impairment. Acta Ophthalmol (Copenh). 1989;67:225–233.

38 Rubin GS, Legge GE. Psychophysics of reading. VI. The role of contrast in low vision. Vision Res. 1989;29:79–91.

39 Rubin GS, Bandeen-Roche K, Huang GH, et al. The association of multiple visual impairments with self-reported visual disability: SEE project. Invest Ophthalmol Vis Sci. 2001;42:64–72.

40 Rubin GS, Bandeen-Roche K, Prasada-Rao P, et al. Visual impairment and disability in older adults. Optom Visual Sci. 1994;71:750–760.

41 Beck RW, Cleary PA, Anderson MM, Jr., et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med. 1992;326:581–588.

42 Rubin GS, Bressler NM. Effects of verteporfin therapy on contrast on sensitivity: results from the Treatment of Age-related macular degeneration with Photodynamic therapy (TAP) investigation – TAP report no 4. Retina. 2002;22:536–544.

43 Patel PJ, Chen FK, Da Cruz L, et al. Contrast sensitivity outcomes in the ABC trial: a randomized trial of bevacizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52:3089–3093.

44 Ginsburg A. Next generation contrast sensitivity testing. In: Rosenthal BP, Cole R. Functional assessment of low vision. St Louis: Mosby Year Book; 1996:77–88.

45 Pomerance GN, Evans DW. Test–retest reliability of the CSV-1000 contrast test and its relationship to glaucoma therapy. Invest Ophthalmol Vis Sci. 1994;35:3357–3361.

46 Jarvinen P, Hyvarinen L. Contrast sensitivity measurement in evaluations of visual symptoms caused by exposure to triethylamine. Occup Environ Med. 1997;54:483–486.

47 Verbaken JH, Johnston AW. Population norms for edge contrast sensitivity. Am J Optom Physiol Opt. 1986;63:724–732.

48 Arditi A. Improving the design of the letter contrast sensitivity test. Invest Ophthalmol Vis Sci. 2005;46:2225–2229.

49 Thayaparan K, Crossland MD, Rubin GS. Clinical assessment of two new contrast sensitivity charts. Br J Ophthalmol. 2007;91:749–752.

50 Pesudovs K, Hazel CA, Doran RM, et al. The usefulness of Vistech and FACT contrast sensitivity charts for cataract and refractive surgery outcomes research. Br J Ophthalmol. 2004;88:11–16.